$158.52
1.44% today
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US5011471027
Symbol
KRYS

Krystal Biotech, Inc. Target price 2024 - Analyst rating & recommendation

Krystal Biotech, Inc. Classifications & Recommendation:

Buy
100%

Krystal Biotech, Inc. Price Target

Target Price $208.00
Price $160.83
Potential
Number of Estimates 8
8 Analysts have issued a price target Krystal Biotech, Inc. 2025 . The average Krystal Biotech, Inc. target price is $208.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 10 Analysts recommend Krystal Biotech, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Krystal Biotech, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Krystal Biotech, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 50.70 291.36
474.67%
EBITDA Margin -181.89% 24.72%
113.59%
Net Margin 22.12% 35.14%
58.84%

9 Analysts have issued a sales forecast Krystal Biotech, Inc. 2024 . The average Krystal Biotech, Inc. sales estimate is

$291m
Unlock
. This is
20.64% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$296m 22.72%
Unlock
, the lowest is
$280m 15.93%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $50.7m
2024
$291m 474.67%
Unlock
2025
$468m 60.65%
Unlock
2026
$677m 44.67%
Unlock
2027
$876m 29.39%
Unlock
2028
$1.1b 23.29%
Unlock

3 Analysts have issued an Krystal Biotech, Inc. EBITDA forecast 2024. The average Krystal Biotech, Inc. EBITDA estimate is

$72.0m
Unlock
. This is
0.68% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$82.3m 15.04%
Unlock
, the lowest is
$63.5m 11.27%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-92.2m 20.60%
2024
$72.0m 178.10%
Unlock
2025
$218m 202.52%
Unlock
2026
$366m 67.83%
Unlock
2027
$513m 40.21%
Unlock
2028
$562m 9.52%
Unlock

EBITDA Margin

2023 -181.89%
2024
24.72% 113.59%
Unlock
2025
46.55% 88.31%
Unlock
2026
54.00% 16.00%
Unlock
2027
58.52% 8.37%
Unlock
2028
51.98% 11.18%
Unlock

1 Analyst has issued a net profit forecast Krystal Biotech, Inc. 2024 . The average Krystal Biotech, Inc. net profit estimate is

$102m
Unlock
. This is
101.14% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$102m 101.14%
Unlock
, the lowest is
$102m 101.14%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $11.2m 107.10%
2024
$102m 812.86%
Unlock
2025
$204m 99.43%
Unlock

Net Margin

2023 22.12%
2024
35.14% 58.84%
Unlock
2025
43.63% 24.16%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share $ 0.39 3.56
107.10% 812.82%
P/E 45.18
EV/Sales 13.88

1 Analysts have issued a Krystal Biotech, Inc. forecast for earnings per share. The average Krystal Biotech, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$3.56
Unlock
. This is
101.13% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$3.56 101.13%
Unlock
, the lowest is
$3.56 101.13%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $0.39 107.10%
2024
$3.56 812.82%
Unlock
2025
$7.10 99.44%
Unlock

P/E ratio

Current 90.98 207.34%
2024
45.18 50.34%
Unlock
2025
22.65 49.87%
Unlock

Based on analysts' sales estimates for 2024, the Krystal Biotech, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

13.88
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
15.88
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 16.75 95.12%
2024
13.88 17.12%
Unlock
2025
8.64 37.75%
Unlock
2026
5.97 30.88%
Unlock
2027
4.62 22.71%
Unlock
2028
3.74 18.89%
Unlock

P/S ratio

Current 19.15 95.31%
2024
15.88 17.11%
Unlock
2025
9.88 37.75%
Unlock
2026
6.83 30.88%
Unlock
2027
5.28 22.71%
Unlock
2028
4.28 18.89%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today